Rapid development of two factor IXa inhibitors from hit to lead.

Bioorg Med Chem Lett

Department of Medicinal Chemistry, Merck Research Laboratories, Merck and Co., Inc, PO Box 2000, E. Lincoln Ave., Rahway, NJ 07016, USA.

Published: June 2015

Two high-throughput screening hits were investigated for SAR against human factor IXa. Both hits feature a benzamide linked to a [6-5]-heteroaryl via an alkyl amine. In the case where this system is a benzimidazolyl-ethyl amine the binding potency for the hit was improved >500-fold, from 9 μM to 0.016 μM. For the other hit, which contains a tetrahydropyrido-indazole amine, potency was improved 20-fold, from 2 μM to 0.09 μM. X-ray crystal structures were obtained for an example of each class which improved understanding of the binding, and will enable further drug discovery efforts.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2015.04.025DOI Listing

Publication Analysis

Top Keywords

factor ixa
8
rapid development
4
development factor
4
ixa inhibitors
4
inhibitors hit
4
hit lead
4
lead high-throughput
4
high-throughput screening
4
screening hits
4
hits investigated
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!